MaxCyte Preliminary Q4 Core Revenue Improves

MaxCyte

4.18 EUR -3.69%

• Charts
• News
• Analysen

Kaufen / Verkaufen

(RTTNews) - MaxCyte, Inc. (MXCT), a cell engineering firm, said on Monday that it expects to post its fourth-quarter core revenue in the range of $8.3 million to $8.5 million, compared with $7.2 million, registered for the same period last year. For the full year, according to the company's preliminary estimates, core revenue is expected to be in the range of $32.2 million to $32.4 million, higher than $29.8 million of the prior year.

Maher Masoud, CEO of MaxCyte, said: "The operating environment in the cell therapy industry is improving as we move into 2025, and we remain confident in the opportunity that exists for MaxCyte in the years ahead. In 2024, we increased the number of SPL customers by six, supported the commercial launch of the first non-viral gene-edited cell therapy product approved by the FDA, and returned to healthy revenue growth while streamlining operations."

The company is expected to release its full-year SPL program-related revenue and total revenue in March.